血清21-脱氧皮质醇用于诊断雄激素过多女性中的非经典型先天性肾上腺皮质增生症
横断面研究纳入99例雄激素过多女性,用LC-MS/MS测定21-脱氧皮质醇(21DF)与17-羟孕酮(17OHP),并以CYP21A2基因分型确认非经典型先天性肾上腺皮质增生症(NCCAH)和杂合子(HTZ)。结果显示LC-MS/MS下NCCAH的17OHP阈值低于免疫法,21DF与17OHP可准确区分HTZ、NCCAH与多囊卵巢综合征(PCOS)。
要点
- LC-MS/MS下基础与刺激后17OHP诊断NCCAH的阈值分别为3.0 nmol/L和20.7 nmol/L。
- 基础与刺激后21DF阈值0.31 nmol/L和13.3 nmol/L对NCCAH灵敏度100%,特异度96.8%和100%。
- 刺激后17OHP 8.0 nmol/L、21DF 1.0 nmol/L及(21DF+17OHP)/皮质醇比值13.6对HTZ灵敏度100%,特异度80.4%、90.5%、85.0%。
核心结论
- LC-MS/MS特异性17OHP诊断NCCAH的阈值低于基于免疫法的阈值。
- LC-MS/MS定量的17OHP和21DF可准确区分HTZ和NCCAH与PCOS。
研究设计与样本
- 横断面研究纳入99例雄激素过多女性,其中2010至2017年接受促肾上腺皮质激素刺激试验(SST)和CYP21A2基因分型者,以及2017至2021年前瞻性招募因雄激素过多症状转诊行SST者。
- 比较基因确诊NCCAH、HTZ和PCOS之间的类固醇水平,并用受试者工作特征分析确定HTZ和NCCAH的最佳17OHP与21DF阈值。
主要发现
- 基础17OHP、刺激后17OHP和21DF分别在99例、85例和42例参与者中测定。
- NCCAH的最佳阈值:基础17OHP为3.0 nmol/L,刺激后17OHP为20.7 nmol/L。
- 基础21DF阈值0.31 nmol/L和刺激后21DF阈值13.3 nmol/L对NCCAH的灵敏度均为100%,特异度分别为96.8%和100%。
- HTZ的诊断阈值:刺激后17OHP 8.0 nmol/L、21DF 1.0 nmol/L和(21DF+17OHP)/皮质醇比值13.6,灵敏度均为100%,特异度分别为80.4%、90.5%和85.0%。
关键数值与推荐
- NCCAH的LC-MS/MS阈值:基础17OHP 3.0 nmol/L,刺激后17OHP 20.7 nmol/L。
- NCCAH的21DF阈值:基础0.31 nmol/L(灵敏度100%,特异度96.8%),刺激后13.3 nmol/L(灵敏度100%,特异度100%)。
- HTZ的阈值:刺激后17OHP 8.0 nmol/L(灵敏度100%,特异度80.4%)、21DF 1.0 nmol/L(灵敏度100%,特异度90.5%)、(21DF+17OHP)/皮质醇比值13.6(灵敏度100%,特异度85.0%)。
临床怎么用
- 在雄激素过多女性中,可采用LC-MS/MS测定的17OHP和21DF区分HTZ、NCCAH与PCOS。
- 诊断NCCAH时应使用LC-MS/MS特异性17OHP阈值,而非免疫法阈值。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Nonclassic congenital adrenal hyperplasia (NCCAH) requires exclusion before diagnosing polycystic ovary syndrome (PCOS). Increasing use of liquid chromatography and tandem mass spectrometry (LC-MS/MS) necessitates revision of immunoassay-based criteria for NCCAH. Measurement of 21-deoxycortisol (21DF) may simplify the diagnosis of heterozygosity (HTZ), the presence of 1 affected CYP21A2 allele, which currently relies on complex molecular studies. OBJECTIVE: We aimed to determine LC-MS/MS-specific criteria for NCCAH and HTZ and compare the diagnostic accuracy of 21DF and 17-hydroxyprogesterone (17OHP). METHODS: A cross-sectional study involving 99 hyperandrogenic females was performed. We identified females who had undergone both a synacthen stimulation test (SST) and CYP21A2 genotyping from 2010 to 2017, and prospectively recruited females referred for an SST to investigate hyperandrogenic symptoms from 2017 to 2021. Steroids were compared between genetically confirmed NCCAH, HTZ, and PCOS. Optimal 17OHP and 21DF thresholds for HTZ and NCCAH were determined by receiver operating characteristic analysis. RESULTS: Basal 17OHP, stimulated 17OHP, and 21DF were measured in 99, 85, and 42 participants, respectively. Optimal thresholds for NCCAH were 3.0 nmol/L and 20.7 nmol/L for basal and stimulated 17OHP, respectively. Basal and stimulated 21DF thresholds of 0.31 nmol/L and 13.3 nmol/L provided 100% sensitivity with specificities of 96.8% and 100% for NCCAH, respectively. Diagnostic thresholds for HTZ of 8.0 nmol/L, 1.0 nmol/L, and 13.6 for stimulated 17OHP, 21DF, and the ratio (21DF + 17OHP)/cortisol each provided 100% sensitivity with specificities of 80.4%, 90.5%, and 85.0%, respectively. CONCLUSION: LC-MS/MS-specific 17OHP thresholds for NCCAH are lower than those based on immunoassay. LC-MS/MS-quantified 17OHP and 21DF accurately discriminate HTZ and NCCAH from PCOS.
引用
- Ng JL, Lim EM, Zhang R, et al. Serum 21-Deoxycortisol for Diagnosis of Nonclassic Congenital Adrenal Hyperplasia in Women With Androgen Excess. J Clin Endocrinol Metab. 2023. PMID: 37358001. doi:10.1210/clinem/dgad377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。